Literature DB >> 1680547

Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2.

L A Maier1, F J Xu, S Hester, C M Boyer, S McKenzie, A M Bruskin, Y Argon, R C Bast.   

Abstract

A murine monoclonal antibody, TA1, is directed against an epitope on the extracellular domain of the HER-2/neu (c-erbB-2) gene product. Requirements for TA1-induced internalization of c-erbB-2 have been studied using the SKBr3 human breast cancer cell line and several rat fibroblast cell lines that express either wild-type or mutant human c-erbB-2. Internalization of TA1 was monitored by assaying protease-resistant uptake of 125I-labeled TA1, by electron microscopy of gold-labeled TA1, and by inhibition of clonogenic growth of cells incubated with TA1 that had been conjugated with blocked ricin. Similar rates of internalization of TA1 were observed in SKBr3 and in rat fibroblasts that expressed human c-erbB-2. The route of endocytosis was the same as that observed with antibodies against other membrane receptors. Anti-c-erbB-2 and anti-transferrin receptor cointernalized through clathrin-coated pits, coated vesicles, endosomes, and multivesicular bodies. Products of mutant c-erbB-2 that lacked a portion of the tyrosine kinase domain or that lacked most of the cytoplasmic domain were endocytosed in the presence of TA1 as promptly as the wild-type c-erbB-2 product. Slightly more rapid internalization of TA1 was observed in rat cells that expressed c-erbB-2 with a single point mutation in the transmembrane domain. Taken together, our data suggest that neither the intracytoplasmic domain nor receptor phosphorylation is required for antibody-mediated endocytosis of c-erbB-2.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1680547

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Association with membrane protrusions makes ErbB2 an internalization-resistant receptor.

Authors:  Anette M Hommelgaard; Mads Lerdrup; Bo van Deurs
Journal:  Mol Biol Cell       Date:  2004-01-23       Impact factor: 4.138

2.  Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.

Authors:  Swapnil S Desale; Srikumar M Raja; Jong Oh Kim; Bhopal Mohapatra; Kruti S Soni; Haitao Luan; Stetson H Williams; Timothy A Bielecki; Dan Feng; Matthew Storck; Vimla Band; Samuel M Cohen; Hamid Band; Tatiana K Bronich
Journal:  J Control Release       Date:  2015-02-03       Impact factor: 9.776

3.  p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy.

Authors:  Yaara Zwang; Yosef Yarden
Journal:  EMBO J       Date:  2006-08-24       Impact factor: 11.598

4.  Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay.

Authors:  J P Vaughn; J D Iglehart; S Demirdji; P Davis; L E Babiss; M H Caruthers; J R Marks
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

5.  Antibody-induced activation of p185HER2 in the human lung adenocarcinoma cell line Calu-3 requires bivalency.

Authors:  U Srinivas; E Tagliabue; M Campiglio; S Ménard; M I Colnaghi
Journal:  Cancer Immunol Immunother       Date:  1993-06       Impact factor: 6.968

6.  Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy.

Authors:  Lilach M Friedman; Ariel Rinon; Bilha Schechter; Ljuba Lyass; Sara Lavi; Sarah S Bacus; Michael Sela; Yosef Yarden
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-31       Impact factor: 11.205

Review 7.  Cancer therapeutic antibodies come of age: targeting minimal residual disease.

Authors:  Tsipi Ben-Kasus; Bilha Schechter; Michael Sela; Yosef Yarden
Journal:  Mol Oncol       Date:  2007-03-14       Impact factor: 6.603

8.  Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.

Authors:  Y Cao; J W Marks; Z Liu; L H Cheung; W N Hittelman; M G Rosenblum
Journal:  Oncogene       Date:  2013-02-04       Impact factor: 9.867

Review 9.  The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.

Authors:  Jaclyn A Freudenberg; Qiang Wang; Makoto Katsumata; Jeffrey Drebin; Izumi Nagatomo; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2009-05-18       Impact factor: 3.362

10.  Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake.

Authors:  E Hurwitz; I Stancovski; M Sela; Y Yarden
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.